Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Sep
16
Today In Oncology
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
New Executive Director of the Duke Cancer Institute Named
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo